SOURCE: BioMedReports


March 24, 2010 11:09 ET

Millennium Biotechnologies Group Inc. (MBTG.OB): An Undervalued Biotech With Multiple Catalysts Poised to See Significant Price Moves in the Short Term

LOS ANGELES, CA--(Marketwire - March 24, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that good things may be on the way for Millennium Biotechnologies Group Inc. (OTCBB: MBTG).

During the past couple of weeks, a few interesting things have happened to this very undervalued "bottom play" in the biotech sector.

The company has not only been going through a very comprehensive capital restructuring, the company which engages in the research, development, and marketing of products for the Clinical Nutrition and Sports Supplement Markets appears to be getting ready to go prime time.

Just a few days ago, they announced that they officially changed their name to Inergetics, Inc.

There is some well sourced chatter that they are close to signing a popular sports figure to endorse their Surgex brand nutritional support formula for athletes.

Intriguing also, is the fact that Ken Sadowsky, a distinguished expert and veteran of the Beverage Industry, has recently rejoined the Company's board of directors. Sadowsky's expertise in functional beverages and his well established relationships with key financing contacts in the industry are extremely important to what the company is getting ready to do -- which is grow, secure a major distributor and boost profits.

Sadowsky is the Senior Beverages Advisor for Verlinvest, a Brussels-based holding company established by the founding family of Interbrew, currently known as Anheuser Busch InBev. The groundwork is now there for a potential investment into the company -- similar to the one that Verlinvest made in 2002 when they put money into Glaceau Vitamin Water -- which helped that company grow very rapidly and was eventually sold to Coca-Cola for $4.1 billion in 2007; resulting in a very high return for Verlinvest. Do not be surprised to see something similar develop here in the very near future.

A complete report on the company is available now at BioMedReports.Com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila, Assistant Editor, BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480 Fax: +1 888 210 3556